Overview

Multi Neuro-functional Biomarkers for Monitoring the Effects of Treatments in ADHD Children

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:
0

Participant gender:
All

Summary

MIMOSA study aims to characterize from behavioral, neurophysiological and neurocognitive perspectives children and adolescents with attention deficit hyperactivity disorder (ADHD), in order to identify a possible biomarker of response to medication treatments. To achieve this aim, in the study children with ADHD (drug naive) are recruited and undergo behavioral and clinical screenings, neurocognitive profile, and neurophysiological evaluation with functional near infrared spectroscopy (fNIRS). ADHD group is evaluated before the beginning of medications, at first dose of medication (only imaging evaluation fNIRS), and after a period of two/three months of continuous treatment with medication.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

IRCCS Eugenio Medea
Maria Nobile

Treatments:

Methylphenidate

Criteria

Inclusion Criteria:

- diagnosis of ADHD according to DSM-5 (Diagnostic and Statistical Manual of Mental
Disorders-5) criteria;

- drug naive

Exclusion Criteria:

- presence of intellectual disability, neurological diseases, epilepsy, genetic
syndromes

- and previous treatment with psychoactive drugs